您当前的位置：
首页 >
文章列表页 >
2025 research hotspots and prospects of endocrine therapy for HR+/HER2- breast cancer
更新时间：2026-04-08

    • 2025 research hotspots and prospects of endocrine therapy for HR+/HER2- breast cancer

    • Chin Oncol   Vol. 36, Issue 2, Pages: 131-140(2026)

    • DOI：10.19401/j.cnki.1007-3639.2026.02.005    

      CLC： R737.9

    • Received：23 January 2026，

      Revised：2026-02-06，

      Published：28 February 2026

    移动端阅览

  • ZHANG L X, GAO Z H, LI N, et al. 2025 research hotspots and prospects of endocrine therapy for HR+/HER2- breast cancer［J］. Chin Oncol, 2026, 36(2): 131-140. DOI： 10.19401/j.cnki.1007-3639.2026.02.005.

  •  
  •  

0

Views

31

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Progress and future directions of important clinical trial on breast cancer in China in 2025
Clinical utility of circulating tumor DNA detection for diagnosis of breast cancer
The clinical value of liquid tumor biomarker detection for breast cancer
Progress and outlook of fundamental and translational breast cancer research in China, 2025

Related Author

DONG Zixian
LI Zhedong
LI Muyao
YU Xinmiao
JIN Feng
叶　青
江泽飞
CHE Xiangxian

Related Institution

Department of Breast Surgery, the First Affiliated Hospital of China Medical University
军事医学科学院附属医院乳腺肿瘤科
Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Department of Breast Surgery, Affiliated Cancer Hospital of Shandong First Medical University
0